

**Funds Raised to date:** \$134M


**OVERVIEW**

Paratek Pharmaceuticals, Inc. is a private biopharmaceuticals company headquartered in Boston, MA, that is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening infectious diseases. Paratek's mission is to develop new antibiotic and anti-infective products that address the major worldwide problem of bacterial resistance and to pursue additional promising applications of the Company's technology into other disease areas such as inflammation.

**PRODUCT RESEARCH AND DEVELOPMENT PROGRAMS**

Paratek has established two product development platforms to identify and develop multiple products for the treatment of infectious and other serious diseases:

- The Tetracycline ("TET") Program is based on Paratek's expertise in medicinal chemistry, from which the Company's lead compound PTK 0796 has now completed a Phase 2 clinical study that was started in July 2007.
- The Multiple Adaptational Response ("MAR") Program is based on novel discoveries in pathogen genomics.

**SUMMARY OF PRODUCT PIPELINE AND DEVELOPMENT STATUS**

**TETRACYCLINE PROGRAM**

When first introduced over 50 years ago, tetracyclines were used as first-line agents against a broad spectrum of bacteria. Worldwide, tetracyclines are still among the most commonly used anti-infective agents to combat bacterial infections. However, emergence of resistance has sharply curtailed their effectiveness as antibiotics, while newly discovered non-antibiotic uses are increasingly driving the use of tetracyclines. Given physicians' familiarity with and acceptance of the tetracyclines such as minocycline and doxycycline, Paratek believes that its ability to create next generation classes of compounds derived from the tetracycline class will yield a diversity of novel, more effective and clinically useful products that may again be used as first line antibiotics and other disease modifying treatments for serious diseases.

**Antibiotics**

Paratek has developed new classes of antibiotics, derived from the tetracycline class, that are designed to inhibit susceptible and multi-drug-resistant bacteria. In animal and human studies these new antibiotics are well tolerated with desirable toxicity and safety profiles.

**COLLABORATORS:**

Families of SMA  
 Merck & Co.  
 MerckSerono  
 Tufts University  
 Warner Chilcott

**INSTITUTIONAL INVESTORS:**

Aisling Capital  
 BankInvest  
 BioFund  
 Bioveda Capital  
 Boston Life Science Venture Corp  
 DE Shaw  
 Formosa Healthcare Investments  
 GeneChem Therapeutics  
 HBM BioVentures  
 Lombard Odier Darier Hentsch  
 Nomura Phase 4  
 Novartis Bioventures  
 Omega Fund  
 POD Holding  
 Wheatley Medtech Partners

**BOARD OF DIRECTORS:**

Walter Gilbert, Ph.D.  
*Chairman of the Board*

Stuart B. Levy, M.D.  
*Vice Chairman & CSO*

Thomas J. Bigger  
*President & CEO, Director*

Kalevi Kurkijarvi, Ph.D.  
*Director*

Kenneth J. Novack  
*Director*

Patricia Smith, M.D.  
*Director*

Pieter Strijkert, Ph.D.  
*Director*

Anthony Y. Sun, M.D.  
*Director*

## **Leading Clinical Program: PTK 0796 for Hospital Infections**

Paratek has discovered a promising new class of antibiotics called the aminomethylcyclines (AMCs), derived from the tetracycline class. The leading AMC in clinical development is PTK 0796, an oral and IV once-daily antibiotic agent with activity against resistant and susceptible gram-positive, gram-negative, atypical and anaerobic bacteria, including multi-drug resistant bacteria, such as methicillin-resistant *Staphylococcus aureus* (MRSA). Paratek is developing PTK 0796 as a first-line agent for empiric therapy primarily for the leading infections requiring hospitalization, such as complicated skin and skin structure infections (cSSSIs) and moderate to severe community-acquired pneumonia (CAP). A Phase 2 cSSSI study was completed in December 2007, where oral and IV forms of PTK 0796 compared very favorably against Zyvox®.

### **Other Compounds**

Paratek is also collaborating with Merck & Co. to develop and commercialize broad-spectrum AMCs for community-acquired respiratory, skin and other community bacterial infections. Antibiotics to treat these infections are developed and marketed to allow treatment of bacterial infections prior to hospitalization and will be distinct from PTK 0796. These antibiotics are still highly active against important susceptible and multi-drug resistant bacteria that are increasingly prevalent in community-acquired infections such as CA-MRSA, MDR-SP and ESBL producing gram-negative bacteria.

Paratek has synthesized more than 2,500 novel tetracycline compounds. These new compounds offer product development opportunities for a number of other antibacterial and non-antibacterial indications, such as acne, multiple sclerosis, spinal muscular atrophy, stroke and certain other inflammation-related disorders (such as rheumatoid arthritis & acute respiratory distress syndrome). Paratek's chemistry expertise and knowledge of the structure activity relationships of the molecules has enabled Paratek to engage in a targeted approach to identify new compounds that have commercial potential. Many of Paratek's new compounds are currently undergoing *in vitro* and *in vivo* testing to assess their use in antibacterial, anti-inflammatory and other therapeutic applications.

### **MAR PROGRAM**

In the MAR Program, Paratek is exploiting its discovery of the mar operon, a novel "master switch" that controls expression of over 80 genes in clinically important bacteria. When activated, the MAR system initiates a number of bacterial survival and defense mechanisms, including processes whereby bacteria establish infections and develop resistance to antibiotics. Paratek has synthesized a series of small organic molecules (MAR inhibitors) that target and inhibit MarA and related proteins. Paratek has shown that these MAR inhibitors prevent infection *in vivo*. MAR inhibitors can be envisioned as broad-spectrum agents that decrease bacterial virulence and prevent infection in many clinically relevant settings where patients are at high-risk of contracting bacterial infections, such as ventilator-associated pneumonia and urinary tract infections. MAR inhibitors may also be useful as adjunct therapy to improve the effectiveness of currently available antibiotics.

### **COMMERCIAL PARTNERSHIPS**

In October 2004, Paratek entered into an agreement with Serono (now MerckSerono) to discover, develop and commercialize an orally-available disease modifying treatment for multiple sclerosis (MS) based on non-antibiotic tetracycline derivatives discovered by Paratek chemists. MerckSerono is responsible for the worldwide development and commercialization of compounds arising from the collaboration. Paratek receives an upfront and milestone payments as well as royalties on any product sales under this agreement. Several lead candidates have been identified and are in development.

Paratek has an agreement with Merck & Co. to develop and commercialize broad spectrum antibiotics for community-acquired infections. Merck is leading research, development, manufacturing and commercialization for these antibiotics. Paratek is participating in worldwide development. Under the agreement, Paratek receives upfront and milestone payments and royalties on community antibiotics sold by Merck. The lead compound in this collaboration is expected to enter clinical development in 2008.

In July 2007, Paratek announced that it entered into an exclusive license agreement with Warner Chilcott Company, Inc. for the development and commercialization of novel, narrow-spectrum antibacterial tetracyclines with potent anti-inflammatory activity for the treatment of acne and rosacea. Warner Chilcott is responsible for clinical development and will have exclusive rights to market the products in the United States while Paratek will participate in preclinical development and manufacturing activities. Under the agreement, Paratek received an upfront payment, is eligible to receive additional development and regulatory related milestones and will earn royalties on U.S. sales. The lead candidate in this program is in preclinical development and expected to enter clinical development in 2009.

## **MANAGEMENT**

Thomas J. Bigger  
*President & Chief Executive Officer*

Stuart B. Levy, M.D.  
*Chief Scientific Officer*

John P. Dunphy  
*Vice President & Chief Financial Officer, Treasurer*

Beverly A. Armstrong, JD, MBA  
*Vice President, General Counsel & Chief Compliance Officer*

S. Ken Tanaka, Ph.D.  
*Vice President, Research and Development*

Sean M. Johnston  
*Vice President, Operations*

Dennis Molnar  
*Vice President, Corporate Development*

---

## **CONTACT DETAILS**

75 Kneeland Street  
Boston, MA 02111  
Tel: 617/275-0040  
Fax: 617/275-0039

[www.paratekpharm.com](http://www.paratekpharm.com)

Investor Relations  
[ir@paratekpharm.com](mailto:ir@paratekpharm.com)

Business Development  
[bd@paratekpharm.com](mailto:bd@paratekpharm.com)

Human Resources  
[hr@paratekpharm.com](mailto:hr@paratekpharm.com)